Travere therapeutics announces achievement of interim proteinuria endpoint in the ongoing phase 3 duplex study of sparsentan in focal segmental glomerulosclerosis

Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment

TVTX Ratings Summary

TVTX Quant Ranking